Ipsen Group to help develop, market tasquinimod for mCRPC

Apparently, over the weekend, Active Biotech completed a deal with the Ipsen Group whereby Ipsen will have responsibilities for the development and marketing of tasquinimod everywhere in the world except North and South America and Japan, where Active Biotech has (so far) retained all development and marketing rights.

As previously reported, Active Biotech recently initiated a randomized, double-blind, multi-center Phase III clinical trial of tasquinimod in asymptomatic or mildly symptomatic, chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC). According to the joint media release, this deal also implies that Ipsen will be responsible for the development and implementation of a “supportive” clinical trial of tasquinimod in advanced prostate cancer  to assist in seeking European approval of the drug. Quite what “supportive” means in that context is unclear. Active Biotech will retain responsibility for the global conduct of the Phase III trial already started.

The Ipsen Group already has experience in the development and marketing of treatments for advanced prostate cancer, since they market sustained-release formulations of the LHRH agonist triptorelin in parts of the world under the brand name Decapeptyl.

2 Responses

  1. Are there any clinical trials located in the United States?

  2. Yup … Most of the sites currently recruiting patients for this Phase III trial are in the USA. See the link in the commentary from April 15.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: